摘要目前,晚期三阴性乳腺癌(triple negative breast carcinoma,TNBC)的药物治疗已取得了一些进展,相应的临床研究即有阳性的结果,也有阴性的结果,都为我们的临床实践带来帮助。其中,靶向治疗尚没有突破,化疗方案的优化方兴未艾,免疫治疗则初现端倪。作者就晚期TNBC的药物治疗进展进行了综述。
1Am6 JC, Spenlehauer C, de Murcia G. The PARP superfamily [J]. Bioessays, 2004, 26(8):882-893.
2Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours [J].Nature, 2012,490 (7418 ) :61-70.
3O' Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase 1~ study of iniparib plus gemcitabine and carboplatin versus gemcit- abine and carboplatin in patients with metastatic triple-negative breast cancer[J]. J Clin Oncol, 2014, 32(34) :3840-3847.
4Hu X, Zhang J, Xu B, et al. Multicenter phase 1I study of apa- tinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer[ J]. Int J Cancer, 2014, 135(8) :1961-1969.
5Baselga J, G6mez P, Greil R, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatln alone in patients with me-tastatic triple-negative breast cancer[ J]. J Clin Oncol, 2013, 31 (20) :2586-2592.
6Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001 : random- ized phase 1I study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer[ J]. J Clin Oncol, 2012, 30(21 ) :2615-2623.
7Tr~dan O, Campone M, Jassem J,et al. Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple- negative breast cancer[ J]. Clin Breast Cancer, 2015,15 ( 1 ) : 8-15.
8Finn RS, Bengala C, Ibrahim N, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study[J]. Clin Cancer Res, 2011, 17(21 ) :6905-6913.
9Ma CX, Ellis M J, Petroni GR, et al. A phase study of UCN- O1 in combination with irinotecan in patients with metastatic triple negative breast cancer[ J]. Breast Cancer Res Treat, 2013, 137 (2) :483-492.
10Kaufman PA, Awada A, Twelves C, et al. Phase m open-label randomized study of eribulin mesylate versus capecitabine in pa- tients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane [ J]. J Clin Oncol, 2015, 33(6) :594-601.
